Allergy Therapeutics (LON:AGY) Sets New 1-Year High – Should You Buy?

Allergy Therapeutics plc (LON:AGY) shares hit a new 52-week high during mid-day trading on Monday . The stock traded as high as GBX 6.34 ($0.08) and last traded at GBX 5.70 ($0.07), with a volume of 973787 shares changing hands. The stock had previously closed at GBX 5.50 ($0.07).

Allergy Therapeutics Stock Performance

The stock has a market cap of £305.28 million, a price-to-earnings ratio of -105.00, a PEG ratio of -30.70 and a beta of 1.40. The firm has a fifty day simple moving average of GBX 5.12 and a 200 day simple moving average of GBX 4.87. The company has a current ratio of 1.40, a quick ratio of 1.48 and a debt-to-equity ratio of 37.22.

Allergy Therapeutics Company Profile

Allergy Therapeutics plc, a commercial biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics.